Comprehensive Management in COPDA Whole Patient Case Series
Do benefits outweigh risks for corticosteroid therapy in acute exacerbation of chronic obstructive pulmonary disease in people with diabetes mellitus?
Aldibbiat AM, Al-Sharefi A. Int J Chron Obstruct Pulmon Dis. 2020;15:567-574.
Cazzola M, Rogliani P, Calzetta L, Lauro D, Page C, Matera MG. Trends Pharmacol Sci. 2017;38(10):940-951.
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial.
Day NC, Kumar S, Criner G, et al. Respir Res. 2020;21(1):139.
Güder G, Störk S. Herz. 2019;44(6):502-508.
Halpin DMG, Dransfield MT, Han MK, et al. Eur Respir J. 2020;55(5):1901921.
Exacerbations of chronic obstructive pulmonary disease and cardiac events. A post hoc cohort analysis from the SUMMIT randomized clinical trial.
Kunisaki KM, Dransfield MT, Anderson JA, et al. Am J Respir Crit Care Med. 2018;198(1):51-57.
Lipson DA, Barnhart F, Brealey N, et al. N Engl J Med. 2018;378(18):1671-1680.
Reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for chronic obstructive pulmonary disease. A randomized, double-blind, multicenter, parallel-group study.
Martinez FJ, Rabe KF, Ferguson GT, et al. Am J Respir Crit Care Med. 2021;203(5):553-564.
Miravitlles M, Auladell-Rispau A, Monteagudo M, et al. Eur Respir Rev. 2021;30(160):210075.
Metabolic effects associated with ICS in patients with COPD and comorbid type 2 diabetes: a historical matched cohort study.
Price DB, Russel R, Mares R, et al. PLoS One. 2016;11(9):e0163903.
Pellicori P, Cleland JGF, Clark AL. Heart Fail Clin. 2020;16(1):33-44.
Rabe KF, Martinez FJ, Ferguson GT, et al. N Engl J Med. 2020;383(1):35-48.
Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.
Vestbo J, Anderson JA, Brook RD, et al. Lancet. 2016;387(10030):1817-1826.
Effects of metformin use on total mortality in patients with type 2 diabetes and chronic obstructive pulmonary disease: a matched-subject design.
Yen FS, Chen W, Wei JCC, Hsu CC, Hwu CM. PLoS One. 2018;13(10):e0204859.
Effects of dapagliflozin in heart failure with reduced ejection fraction, and chronic obstructive pulmonary disease: an analysis of DAPA-HF.
Dewan P, Docherty KF, Bengtsson O, et al. Eur J Heart Fail. 2021;23(4):632-643.
Dransfield MT, Voelker H, Bhatt SP, et al. N Engl J Med. 2019;381(24):2304-2314.
Clinical Practice Tools and Resources
The COPD Pocket Guide, provided by the COPD Foundation, contains comprehensive management information as well as resource tools. It can be downloaded onto any mobile device.
The mMRC scale, provided by MDCalc, allows for the baseline stratification of dyspnea in COPD, as well as other respiratory diseases.
The CAT, provided by the American Academy of Family Physicians, allows assessment of the global impact of COPD (cough, sputum, dyspnea, chest tightness) on patient health status.
The PHQ-9 is a short, validated screening tool to assess a patient’s depression severity.
Patient Resources and Advocacy Organizations
The COPD Pocket Guide for Patients was designed to improve disease management and communication with a patient’s health care team. It includes patient resources such as inhaler and exercise videos as well as tools such as the wallet card and daily symptom tracker that help collect and share information with the health care team. It can be downloaded onto any mobile device.
The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy, and research.
The COPD Foundation’s mission is to prevent and cure COPD and to improve the lives of all people affected by COPD.
GOLD partners with health care professionals and public health officials to raise awareness of COPD and to improve prevention and treatment of this lung disease for patients around the world.
National Jewish Health integrates the latest scientific discoveries with coordinated care for lung, heart, and immune diseases. Their Patient Education Program provides many free educational opportunities and support groups to assist patients and caregivers with managing illnesses and chronic conditions, such as COPD.
Overcoming Pain and Gastrointestinal Distress to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Proactive Diagnosis and Targeted Management
Differential Diagnosis and Comprehensive Management Strategies
Optimizing Maintenance Therapy Across Healthcare Settings
Evolving Strategies for Diagnosis and Long-Term Management
Consensus and Controversies for Responsible Opioid Prescribing
Best Practices in Combination Therapy
Evolving Approaches to Insulin Based Therapy
Improving Outcomes for Patients with COPD
New Strategies for Insulin Replacement Therapy
Clinical Updates in LDL-C Management
Improving Comprehensive Patient Care
Identifying Patients and Tailoring Therapy
Collaborative Approaches to Guideline-Concordant Patient Care
New Strategies for Individualizing Long-term Care
A Focus on Patients With Opioid-Induced Constipation
Consensus and Controversies Across the Spectrum of Patient Presentations
A New Era in Precision Medicine
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Evolving Best Practices to Optimize Outcomes
Consensus and Controversies on the Road to Precision Medicine
Ongoing Monitoring, Pulmonary Rehabilitation, and Individualized Care
The PCP’s Role in Timely Recognition and Referral
Debates and Discussions About Personalizing Patient Management
Differential Diagnosis, Multidisciplinary Management, and Patient Engagement
Key Issues Impacting OB/GYN Practice
From Guideline Recommendations to Daily Clinical Decision-Making
Improving Patient Outcomes Through Shared Clinical Decision Making
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Improving Patient Outcomes Through Shared Clinical Decision Making
Digging Deep on Shared Decision-Making
Mechanistic Insights and Evolving Treatment Options
Clinical Resource Center
A Case-Based Conversation on Managing Asthma and Chronic Rhinosinusitis With Nasal Polyposis
The Clinical and Utilization Benefits of Exacerbation Prevention
Mechanistic Insights and Emerging Treatment Options
A PrEP Primer
A Foundation for Managed Care
A Focus on Exacerbation Prevention
Cardiovascular and Renal Outcomes With SGLT2 Inhibitors
Best Practices for Primary Care
New Paths to Chronic Pain Management
What the Pharmacist Needs to Know about PrEP
Unlocking Novel Paths to Patient Care
Evolving Best Practices for Patient Management
The Increasing Role of JAK Inhibitors
Shared Decision-making in the Era of Biologics
New Pathways to Patient Management
From Comprehensive Patient Evaluations to Individualized Evidence-based Care
Preventing COPD Exacerbations to Improve Outcomes
Debates and Discussions about Monoclonal Antibody Therapies
An Update on Monoclonal Antibody Therapies
New Avenues to the Management of Severe Asthma
Establishing Clinical Readiness Through Mentored Learning
Evolving Best Practices for Pediatric Patients
Interdisciplinary Strategies for Adult and Pediatric Patients